Efficacy and safety of irreversible electroporation combined with immunotherapy in treatment of unresectable pancreatic cancer： A Meta-analysis
Journal Title: Journal of Clinical Hepatology - Year 2024, Vol 40, Issue 11
Abstract
[Objective] To systematically review the safety and efficacy of irreversible electroporation （IRE） combined with immunotherapy in patients with unresectable pancreatic cancer. [Methods] This study was conducted according to the PRISMA guideline， with a PROSPERO registration unmber of CRD42024531984. Datebases including PubMed， Embase the Cochrane Library， Web of Science， CNKI， Wanfang Data， and VIP were searched for related articles on IRE combined with immunotherapy for unresectable pancreatic cancer published up to February 2024. The articles were screened and related data were extracted according to the established inclusion and exclusion criteria， and the quality of the articles was assessed. Review Manager 5.3 and Stata 17.0 software were used to perform the meta-analysis. [Results] Six studies were finally included， with three prospective studies， two retrospective studies， and one randomized controlled trial. There were 376 patients with unresectable pancreatic cancer in total， among whom there were 222 patients in the IRE group and 154 patients in the IRE+immunotherapy group. The meta-analysis showed that compared with IRE alone， IRE combined with immunotherapy significantly prolonged progression-free survival （hazard ratio ［HR］=0.82， 95% confidence interval ［CI］： 0.72 — 0.92， P=0.001） and overall survival （HR=0.86， 95%CI： 0.80 — 0.93， P=0.000 1）， increased T lymphocyte count in the patients （mean difference=217.93， 95%CI： 192.87 — 242.99， P<0.000 01）， and improved the immune function of patients. However， there were no significant differences between the two groups in reducing the incidence rate of adverse events （odds ratio ［OR］=1.43， 95%CI： 0.76 — 2.72， P=0.27） and improving the objective remission rate of patients （OR=1.49， 95%CI： 0.87 — 2.56， P=0.15）. [Conclusion] IRE combined with immunotherapy is safe and effective in patients with unresectable pancreatic cancer and can significantly improve overall survival and progression-free survival and enhance immune function， with little effect on objective remission rate and the incidence rate of adverse events.
Authors and Affiliations
Jian YE, Junfeng YANG, Liwen DU, Jiansheng LIU
Keywords
Related Articles
- EP ID EP753502
- DOI 10.12449/JCH241122
- Views 5
- Downloads 1
Advances in the application of endoscopic ultrasonography in the diagnosis and treatment of cholangiocarcinoma
Endoscopic ultrasonography （EUS） can not only directly observe the morphology of the lumens of the digestive tract through the endoscope， but also perform real-time dynamic ultrasound scanning to obtain the layers of...
Unified consensus and evolution of the definition of acute-on-chronic liver failure： Seeking common ground while reserving differences
The concept of acute-on-chronic liver failure （ACLF） has been introduced for nearly 30 years， and with extensive research on its pathogenesis， diagnostic criteria， and treatment strategies， related consensus statem...
Efficacy and safety of irreversible electroporation combined with immunotherapy in treatment of unresectable pancreatic cancer： A Meta-analysis
[Objective] To systematically review the safety and efficacy of irreversible electroporation （IRE） combined with immunotherapy in patients with unresectable pancreatic cancer. [Methods] This study was conducted accordi...
Expression of CXCL10 and CXCL12 in gallbladder carcinoma and their mechanism of action in tumor invasion
[Objective] To investigate the expression levels of CXCL10 and CXCL12 in gallbladder carcinoma and their mechanism of action in tumor invasion. [Methods] Tumor tissue samples and adjacent tissue samples were collected fr...
An excerpt of American College of Gastroenterology guidelines： Management of acute pancreatitis （2024）
The American College Gastroenterology （ACG） recently released the 2024 edition of Guidelines for the management of acute pancreatitis. The guidelines first discuss the diagnosis， etiology， severity， and early manage...